WO2000007595A1 - Pyridinones for the treatment of sexual dysfunction - Google Patents
Pyridinones for the treatment of sexual dysfunction Download PDFInfo
- Publication number
- WO2000007595A1 WO2000007595A1 PCT/EP1999/005544 EP9905544W WO0007595A1 WO 2000007595 A1 WO2000007595 A1 WO 2000007595A1 EP 9905544 W EP9905544 W EP 9905544W WO 0007595 A1 WO0007595 A1 WO 0007595A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- methyl
- halo
- composition
- hydrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Definitions
- This invention relates to pyridinone compounds with therapeutic activity, and to therapeutic compositions containing such compounds. More particularly, the invention relates to compositions and methods for treating sexual dysfunction in animals and humans, and still more particularly to the treatment of penile erectile dysfunction in human males.
- Impotence is defined as a lack of the ability of a male to copulate, and very often involves an inability to achieve penile erection or ejaculation, or both. More specifically, penile erectile impotence or dysfunction may be defined as the inability to obtain or sustain an erection adequate for intercourse.
- the prevalence of male impotence is claimed to be between 2 and 7% of the human male population, increasing with age, up to 50 years of age, and between 18 and 75% between 55 and 80 years of age. In the USA alone, for example, it has been estimated that there are up to 10 million impotent males, with the majority suffering from problems of organic rather than psychogenic origin.
- KCO Potassium channel openers
- VIP vasoactive intestinal poly- peptide
- GTN glyceryl trinitrate
- orally administered drugs comprising pyrazolopyrimidinones are being used to treat penile erectile dysfunction in human males.
- drugs e.g., Viagra®
- cGMP PDEs potent inhibitors of cyclic guanosine 3', 5 ' -monophosphate phosphodiesterases
- cAMP PDEs cyclic adenosine 3', 5' -monophosphate phosphodiesterases
- the invention is directed to pyridinone compounds with therapeutic activity, and to therapeutic compositions containing such compounds, wherein the compounds have the general formula I:
- Ri is hydrogen, lower alkyl optionally substituted by hydroxy or C ⁇ _ 4 alkoxyearbonyl, allyl, propynyl or phenyl-lower alkyl in which the phenyl ring is optionally substituted by 1 or 2 C ⁇ - alkoxy groups ;
- R is hydrogen or lower alkyl
- R 3 is (X) m -S (0) n R 4 , COR 5 , SR 6 , or S (OH) (0)NR 7 , wherein m is 0 or 1, n is 0, 1, or 2, X is oxygen or lower alkylene, R is C ! - 4 alkyl, R 5 is hydroxyl, lower alkyl carbonyl, amino, or lower alkyl amino, and Re and R are lower alkyl; and
- ring A represents an optionally substituted phenyl ring of formula
- R 3 , R 9 and R J _Q which may be the same or different, are hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, halo, tri - fluoromethyl, lower alkylthio, lower alkylsulphinyl, loweralkyl- sulphonyl, halogenated lower alkyl, halogenated lower alkoxy, cyano, phenyl, or phenyl substituted by 1 to 3 groups indepen- dently selected from lower alkyl, lower alkoxy and trifluoromethyl ; or
- ring A represents an optionally substituted thiophene ring of formula
- R n is hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, halo, trifluoromethyl, lower alkylthio, phenyl, or phenyl substituted by halogen, or a pharmaceutically acceptable salt thereof.
- the compounds of the general formula I have been found to have antihypertensive activity and cardiac activity in warm-blooded animals.
- the compounds, methods of making the compounds, antihy- pertensive and cardiac therapeutic compositions of the compounds, and methods for treating hypertension and heart failure using the compounds are described in US Patent 4,302,460, US Patent 4,522,884, US Patent 4,855,291, US Patent 4,877,793, US Patent 4,710,506, US Patent 4,772,614 and US Patent 4,997,840, the dis- closures of which patents are expressly incorporated herein, in their entirety, by reference.
- the compounds of formula I are useful in the treatment of sexual dysfunction in animals and humans, more particularly penile erectile dysfunction in human males.
- the compositions and methods of the invention are envisaged primarily for the treatment of erectile dysfunction or male sexual dysfunction, they may also be useful for the treatment of female sexual dysfunction including orgasmic dysfunction related to clitoral disturbances.
- the invention concerns pharmaceutical compositions useful for treating sexual dysfunction in humans animals, more particularly penile erectile dysfunction in human males, which comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceuti- cally acceptable diluent or carrier.
- the invention concerns a method for treating sexual dysfunction in humans and animals, more particularly penile erectile dysfunction in human males, which comprises ad- ministering to a human or an animal in need of said treatment an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising either the compound or the salt.
- the invention concerns a process for preparing a pharmaceutical composition for treating sexual dysfunction in humans and animals, more particularly penile erectile dysfunction in human males, which comprises formulating a compound of formula I, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable diluent or carrier.
- the present invention provides pharmaceutical compositions for the treatment of sexual dysfunction in animals and humans, methods for treating sexual dysfunction in animals and humans, processes for preparing the pharmaceutical compositions, using the compounds of the general formula I.
- lower alkyl denote such groups containing 1-8 carbon atoms, especially 2-4 carbon atoms for lower alkanoyl and 1-4 carbon atoms for the other groups .
- Examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-heptyl, n-octyl, methoxy, ethoxy, propoxy, n-butoxy, isobutoxy, acetyl, propionyl, butyryl, methylthio, ethylthio, propylthio and n-butylthio.
- active compound denotes a pyridinone compound of general formula I.
- the active compound may be administered orally, rectally or parenter- ally, preferably orally.
- treatment is used herein in its broadest sense, and includes curative and/or prophylactic treatment of sexual dysfunction in animals and humans .
- animal denotes all warm-blooded ani- mals, including mammals, more preferably human beings.
- the invention provides pharmaceutical compositions comprising compounds of the general formula I, and methods using the compositions to treat sexual dysfunction in male animals and humans, more preferably penile erectile dysfunction in human males .
- the compounds of the invention may contain one or more asymmetric centers and, therefore, can exist as enantiomers or diastereoi- somers .
- certain compounds of the invention containing alkenyl groups may exist as cis-isomers or trans-isomers .
- the invention includes both mixtures and separate in- dividual isomers.
- the compounds may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers .
- Preferred compounds for use in the pharmaceutical compositions and methods of the invention are compounds having the general formulas II and III:
- R 3 is (X) m -S (0) n R 4 , C0R 5 , SR 6 , or S (OH) (0) NR 7 ;
- R 9 is hydrogen and R 10 is halo; lower alkyl, lower alkoxy, trifluoromethyl or lower alkyl-thio;
- Rio is halo, lower alkoxy or lower alkyl and Rg is 6-lower alkyl, 6-lower alkoxy or 6-halo of a different value from Rio; or
- Preferred embodiments include compounds of formula IIA wherein R x and R 2 are methyl, R 9 is hydrogen and Rio is halo, lower alkyl or trifluoromethyl. More preferably, R 10 is halo or C ⁇ C 4 alkyl. In yet another preferred embodiment, Rg is 6-lower alkoxy and R 10 is halo or lower alkoxy. In a further preferred embodiment, Rg is 6-halo and R X o is lower alkoxy. In another preferred embodiment, Rio is C 1 -C 4 alkyl.
- preferred embodiments include compounds of formula IIB, IIC, IID, HE, IIF. IIIA and IIIB as follows:
- Preferred compounds of formula IIB are those in which m is 1, n is 2, and X is oxygen.
- Preferred compounds of formula IIC include those in which m is 0, n is 1 or 2 , and R is methyl.
- Preferred compounds of formula IID include those in which R 5 is amino or lower alkyl amino.
- Preferred compounds of formula HE include those in which R 6 is methyl.
- Preferred compounds of formula IIF include those in which R 7 is methyl.
- Preferred compounds of formula IIIA include those in which n is 1 and R 4 is methyl.
- Pre- ferred compounds of formula IIIB include those in which R 5 is amino or lower alkyl amino.
- Specific preferred compounds of the invention include l-methyl-3-methylsulphinyl-4-quinolone, 7-fluoro-l-methyl-3-me- thylsulphinyl-4-quinolone, 7-fluoro-l-methyl-4-oxo-l, 4-dihydro- quinolone-3-carboxamide, 4-methyl-7-oxo-4 , 7-dihydro- thieno [3 , 2-b] pyridine-6-carboxamide, 4-methyl-6-methylsulphi - nyl-7 (4H) -thieno [3 , 2-b] pyridinone, 7-chloro-l-methyl-3-methylsul- phamoyl-4-quinolone, l-methyl-4-oxo-l, 4-dihydroquinol-3-yl metha- nesulphonate, 7-chloro-l-methyl-4-oxo-l, 4-dihydroquinoline-3-car- boxamide, 7-fluor
- compositions of the present invention may take the form of any of the known pharmaceutical compositions for oral, rectal, parenteral, or topical/transdermal administration.
- Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy.
- the composi- tions of the invention contain 0.1-90% by weight of active compound.
- the compositions of the invention are generally prepared in unit dosage form.
- compositions for oral administration are the preferred composi- tions of the invention, and the active ingredient in such compositions is preferably administered in unit dosage form.
- Preferred compositions are the known pharmaceutical forms for such administration, for example, tablets, capsules, syrups and aqueous or oily suspensions.
- the tablets and capsules may conve- niently contain a unit dosage of the active compound of 1-500 mg/kg, more preferably 5-100 mg/kg, still more preferably 5-50 mg/kg .
- excipients used in the preparation of the compositions of the invention are the excipients well known in the pharmacists' art.
- Tablets may be prepared by mixing the active compound with an inert diluent such as calcium phosphate in the presence of disintegrating agents, for example, maize starch, and lubricating agents, for example, magnesium stearate, and tableting the mix- ture by known methods.
- Such tablets may, if desired, be provided with enteric coatings by known methods, for example, by the use of cellulose acetate phthalate.
- capsules, for example, hard or soft gelatin capsules, containing the active compound with or without added excipients may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner .
- compositions for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non toxic suspending agent such as sodium carboxymethyl-cellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example, arachis oil.
- a non toxic suspending agent such as sodium carboxymethyl-cellulose
- oily suspensions containing a compound of the present invention in a suitable vegetable oil for example, arachis oil.
- compositions of the invention suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases .
- compositions of the invention suitable for parenteral (e.g., sub- lingual or buccal) administration are the known pharmaceutical forms for such administration, for example, sterile suspensions in aqueous and oily media or sterile solutions in a suitable solvent.
- compositions of the invention suitable for topical/transdermal administration are the known pharmaceutical forms for such administration, for example, patches, gels, creams lotions, sprays, etc.
- the compounds of the present invention may be beneficial to use in the form of particles of very small size, for example, as obtained by fluid energy milling. In other formulations, it may be beneficial to use pharmaceutically ac- ceptable salts of the compounds.
- the pharmaceutically acceptable salts of the compounds of the invention which contain a basic center are, for example, non-toxic acid addition salts formed with inorganic acids such as hydro- chloric, hydrobromic, sulfuric and phosphoric acid, with organo- carboxylic acids, or with organo-sulphonic acids.
- Compounds of the invention can also provide pharmaceutically acceptable metal salts, in particular non-toxic alkali metal salts, with bases. Examples include sodium and potassium salts.
- the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.
- the compounds of the invention are administered as a suitably acceptable formulation in accordance with normal veterinary practice.
- the veterinary surgeon will determine the dosing regimen and route of administration most appropriate for a particular animal.
- the therapeutic activity of the compounds of general formula I has been demonstrated by means of tests on standard laboratory animals. Such tests include, for example, the oral and/or intra- duododenal administration of the compounds to rabbits and marmo- sets. Penile erection was elicited in both species upon administration of the compounds of the invention.
- the compounds of the invention are arteriovenous dilators whose clinically relevant pharmacologic mechanism is distinct from compounds such as the pyrazolopyriimidinones of WO 94/28902 that produce vasodilatation by inhibiting the hydrolysis of cyclic GMP by one or more phosphodiesterase isoenzymes.
- Example 1 The five compounds described in Example 1 were tested for penile erectile activity in marmosets as follows.
- Each animal was provided with 80 g of solid diet (predominantly fruit) daily. During the treatment periods, diet was offered approximately 3 hours after dose administration. Tap water was 20 available at all times from a water bottle. The marmosets were housed individually.
- the temperature of the room in which the marmosets were housed was 20-24°C and the relative humidity was within 25 the range of 40-87%. Lighting was by fluorescent light on a 12 hour/12 hour light/dark cycle, which switched on automatically at 0700 hour GMT.
- the test substance was milled.
- the control article and vehicle for the test substance was a 0.4% solution of Cellosize (hydroxyethyl cellulose Q.P. 15000), in pu- 35 rified water B.P. The solution was prepared and used for periods up to 14 days .
- test substance was administered as an oral dose in the ve- 45 hide, at a dose volume of 0.5 ml per 100 g body weight.
- the control group received the vehicle orally, at the same dosage volume.
- the doses were administered by oral gavage, using a Franklin 10FG catheter and a plastic syringe. Doses in the range of 1 mg/kg to 250 mg/kg were employed as appropriate.
- the male marmosets were observed continuously for at least 6 hours after each dose for the occurrence of penile erection.
- Penile erection was observed between 13 minutes after dosing and 2.5 hours from dosing. In certain cases penile erection was maintained for a period of up to 3.5 hours after dosing, in certain cases for up to 7.5 hours after dosing.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99941495A EP1107759A1 (en) | 1998-08-03 | 1999-07-31 | Pyridinones for the treatment of sexual dysfunction |
JP2000563280A JP2002522388A (en) | 1998-08-03 | 1999-07-31 | Pyridinone for the treatment of sexual dysfunction |
AU55090/99A AU5509099A (en) | 1998-08-03 | 1999-07-31 | Pyridinones for the treatment of sexual dysfunction |
CA002339484A CA2339484A1 (en) | 1998-08-03 | 1999-07-31 | Pyridinones for the treatment of sexual dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9506098P | 1998-08-03 | 1998-08-03 | |
US60/095,060 | 1998-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000007595A1 true WO2000007595A1 (en) | 2000-02-17 |
Family
ID=22249125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/005544 WO2000007595A1 (en) | 1998-08-03 | 1999-07-31 | Pyridinones for the treatment of sexual dysfunction |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1107759A1 (en) |
JP (1) | JP2002522388A (en) |
AU (1) | AU5509099A (en) |
CA (1) | CA2339484A1 (en) |
WO (1) | WO2000007595A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1079764A1 (en) * | 1998-05-01 | 2001-03-07 | RT Alamo Ventures Inc. | The treatment of sexual dysfunction in certain patient groups |
WO2002019997A1 (en) * | 2000-09-01 | 2002-03-14 | Cutler Neal R | Pde iii inhibitors for treating sexual dysfunction |
WO2002058703A2 (en) * | 2001-01-26 | 2002-08-01 | R.T. Alamo Ventures I, Llc | The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers |
US6562838B2 (en) | 2001-01-26 | 2003-05-13 | R. T. Alamo Ventures I, L.L.C. | Treatment of cardiovascular disease with quinolinone enantiomers |
WO2003059912A1 (en) * | 2002-01-14 | 2003-07-24 | Pharmacia & Upjohn Company | Oxothieno (3, 2-b) pyridinecarboxamides as antiviral agents |
US6852731B2 (en) | 2002-01-14 | 2005-02-08 | Pfizer | Antiviral compounds |
US6878705B2 (en) | 2002-01-14 | 2005-04-12 | Pfizer | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents |
US6924283B2 (en) | 2001-08-30 | 2005-08-02 | Pfizer | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents |
US10457679B2 (en) | 2015-09-17 | 2019-10-29 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
US10844055B2 (en) | 2016-10-21 | 2020-11-24 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2468367A1 (en) * | 1979-03-27 | 1981-05-08 | Boots Co Ltd | THERAPEUTIC COMPOSITIONS BASED ON QUINOLONES |
EP0172004A2 (en) * | 1984-08-15 | 1986-02-19 | The Boots Company PLC | Quinolinones, process for their preparation and pharmaceutical compositions containing them |
US4710506A (en) * | 1985-06-15 | 1987-12-01 | The Boots Company Plc | Antihypertensive thienopyridines |
US4772614A (en) * | 1985-06-15 | 1988-09-20 | The Boots Company | Quinolone sulphonamides useful as antihypertensive agents |
US4877793A (en) * | 1986-11-20 | 1989-10-31 | The Boots Company, Plc | Thieno[3,2-b]pyridine-6-carboxamide compounds useful in treating hypertension |
US4997840A (en) * | 1988-02-22 | 1991-03-05 | The Boots Company, Plc | Quinolone sulphonates having antihypertensive activity |
WO1994002144A1 (en) * | 1992-07-21 | 1994-02-03 | The Boots Company Plc | Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris |
-
1999
- 1999-07-31 CA CA002339484A patent/CA2339484A1/en not_active Abandoned
- 1999-07-31 AU AU55090/99A patent/AU5509099A/en not_active Abandoned
- 1999-07-31 EP EP99941495A patent/EP1107759A1/en not_active Withdrawn
- 1999-07-31 WO PCT/EP1999/005544 patent/WO2000007595A1/en not_active Application Discontinuation
- 1999-07-31 JP JP2000563280A patent/JP2002522388A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2468367A1 (en) * | 1979-03-27 | 1981-05-08 | Boots Co Ltd | THERAPEUTIC COMPOSITIONS BASED ON QUINOLONES |
US4302460A (en) * | 1979-03-27 | 1981-11-24 | The Boots Company Limited | 4-Quinolinones having antihypertensive activity |
EP0172004A2 (en) * | 1984-08-15 | 1986-02-19 | The Boots Company PLC | Quinolinones, process for their preparation and pharmaceutical compositions containing them |
US4855291A (en) * | 1984-08-15 | 1989-08-08 | The Boots Company Plc | 1,4dihydroquinoline-3-carboxamides |
US4710506A (en) * | 1985-06-15 | 1987-12-01 | The Boots Company Plc | Antihypertensive thienopyridines |
US4772614A (en) * | 1985-06-15 | 1988-09-20 | The Boots Company | Quinolone sulphonamides useful as antihypertensive agents |
US4877793A (en) * | 1986-11-20 | 1989-10-31 | The Boots Company, Plc | Thieno[3,2-b]pyridine-6-carboxamide compounds useful in treating hypertension |
US4997840A (en) * | 1988-02-22 | 1991-03-05 | The Boots Company, Plc | Quinolone sulphonates having antihypertensive activity |
WO1994002144A1 (en) * | 1992-07-21 | 1994-02-03 | The Boots Company Plc | Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris |
Non-Patent Citations (1)
Title |
---|
IKEZONO ET AL.: "General pharmacological properties of the new vasodilator flosequinan", ARZNEIM. FORSCHUNG, vol. 42, no. 10, 1992, pages 1200 - 1211, XP002125660 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1079764A1 (en) * | 1998-05-01 | 2001-03-07 | RT Alamo Ventures Inc. | The treatment of sexual dysfunction in certain patient groups |
EP1079764A4 (en) * | 1998-05-01 | 2001-09-12 | Rt Alamo Ventures Inc | The treatment of sexual dysfunction in certain patient groups |
WO2002019997A1 (en) * | 2000-09-01 | 2002-03-14 | Cutler Neal R | Pde iii inhibitors for treating sexual dysfunction |
WO2002058703A2 (en) * | 2001-01-26 | 2002-08-01 | R.T. Alamo Ventures I, Llc | The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers |
US6562838B2 (en) | 2001-01-26 | 2003-05-13 | R. T. Alamo Ventures I, L.L.C. | Treatment of cardiovascular disease with quinolinone enantiomers |
WO2002058703A3 (en) * | 2001-01-26 | 2003-08-14 | R T Alamo Ventures I Llc | The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers |
US6924283B2 (en) | 2001-08-30 | 2005-08-02 | Pfizer | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents |
US6861438B2 (en) | 2002-01-14 | 2005-03-01 | Pfizer | Antiviral agents |
US6852731B2 (en) | 2002-01-14 | 2005-02-08 | Pfizer | Antiviral compounds |
US6878705B2 (en) | 2002-01-14 | 2005-04-12 | Pfizer | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents |
WO2003059912A1 (en) * | 2002-01-14 | 2003-07-24 | Pharmacia & Upjohn Company | Oxothieno (3, 2-b) pyridinecarboxamides as antiviral agents |
US10457679B2 (en) | 2015-09-17 | 2019-10-29 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
US10882858B2 (en) | 2015-09-17 | 2021-01-05 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
US11613539B2 (en) | 2015-09-17 | 2023-03-28 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
US10844055B2 (en) | 2016-10-21 | 2020-11-24 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
US11530213B2 (en) | 2016-10-21 | 2022-12-20 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
Also Published As
Publication number | Publication date |
---|---|
AU5509099A (en) | 2000-02-28 |
CA2339484A1 (en) | 2000-02-17 |
EP1107759A1 (en) | 2001-06-20 |
JP2002522388A (en) | 2002-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8119649B2 (en) | Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia | |
RU2373938C2 (en) | Pirazile pyrimidinones for impotency treatment | |
WO2000007595A1 (en) | Pyridinones for the treatment of sexual dysfunction | |
CZ20023078A3 (en) | Use of pyrido[3,2-E]-pyrazinones as phosphodiesterase inhibitors 5 for treating erectile dysfunction | |
US20200230143A1 (en) | Therapeutic methods and compositions | |
US20210030741A1 (en) | Pharmaceutical combination of everolimus with dactolisib | |
AU749703B2 (en) | Combination therapy for modulating the human sexual response | |
US20020143030A1 (en) | Treatment of gastroparesis in certain patient groups | |
CZ20012627A3 (en) | Use of imidazo [1,5-a]pyrido [3,2-e]pyrazinones as medicaments | |
US6465465B1 (en) | Process for the treatment of erectile dysfunction and product therefor | |
Kim | Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey | |
NZ217431A (en) | Synergistically antimalarial combination preparations comprising an iron(iii) chelating agent and a schizontocide | |
MXPA01001263A (en) | Pyridinones for the treatment of sexual dysfunction | |
CN108623560A (en) | A kind of Quinolone acid analog derivative and its preparation method and application | |
Lemke | Antiparasitic agents | |
MXPA05000726A (en) | Medicinal composition for treating arteriosclerosis. | |
US20160235710A1 (en) | Composition for treating or preventing erectile dysfunction comprising ldd175 as active ingredient | |
Stork | Antibacterials, antifungals, and antivirals | |
WO1997037657A1 (en) | Anti-hiv composition containing imidazole derivative | |
WO2004069167A2 (en) | Method and compositions for treating male infertility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BG BR BY CA CN CZ GE HR HU ID IL IN JP KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999941495 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2339484 Country of ref document: CA Kind code of ref document: A Ref document number: 2339484 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/001263 Country of ref document: MX Ref document number: 09762371 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999941495 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999941495 Country of ref document: EP |